---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-125484"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2025-05-23T23:59:59+00:00"
generated_at: "2026-05-20T15:18:03.948242+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics shareholders approve reverse stock split at 1:10-1:30 ratio

## Summary
- Elected directors William Ringo (8.9M for) and John Celebi (9.2M for) to three-year terms.
- Ratified Deloitte & Touche as independent auditor for FY2025: 15.8M for, 369.9K against.
- Approved reverse stock split authorization (ratio 1:10 to 1:30) at board discretion; 14.7M for, 1.6M against.

## SEC filing metadata
- accession: 0001193125-25-125484
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2025-05-23T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312525125484/0001193125-25-125484-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312525125484/d13190d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-125484
- JSON: https://secwatch.observer/filing/0001193125-25-125484.json
- Plain text: https://secwatch.observer/filing/0001193125-25-125484.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.